Tarsus Pharmaceuticals, Inc.
NASDAQTarsus Pharmaceuticals just handed bears a difficult week, reporting Q1 results that cleared consensus by a wide margin — and doing so into a short interest position that has already been steadily unwinding. The numbers were unambiguous. Q1 EPS came in at -$0.16, beating the -$0.33 estimate by $0.17. Revenue of $162.1 million topped the $148.4 million consensus. Management…
Snapshot as of 7 May 2026
Tarsus Pharmaceuticals just handed bears a difficult week, reporting Q1 results that cleared consensus by a wide margin — and doing so into a short interest position that has already been steadily unwinding. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TARS — free to start on ORTEX.
Sign up for free →Open TARS on ORTEX